Before Florence pummeled the East Coast, ultimately killing at least 17 people and causing untold millions in damage, some of the world’s largest pharmaceutical companies wrestled with a major dilemma: Should they suspend operations at manufacturing plants in North Carolina, South Carolina, and Virginia, risking shortages of important drugs and vaccines?
GlaxoSmithKline (GSK) chose to close a plant that makes asthma inhalers, while Novartis (NVS) shut down a facility that manufactures oral-dosage generic drugs. Pfizer (PFE) and Merck, meanwhile, decided to scale back operations at multiple North Carolina facilities, closing some entirely.
Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
